Group 1 - Suzhou Gaoxin District's company BoKangShiYun Biopharmaceutical Technology (Suzhou) Co., Ltd. was listed on the Hong Kong Stock Exchange on July 3, with an issue price of HKD 10.1 and a total fundraising amount of HKD 612 million [1] - BoKangShiYun is an innovative clinical-stage ophthalmic biotechnology company focused on developing novel and differentiated therapies, with a pipeline of 7 candidate drugs targeting major diseases of the eye [1] - The core product CBT-001, a global first for treating pterygium eye surface disease, is currently in Phase III clinical trials, while CBT-009 for treating juvenile myopia is expected to enter Phase III trials by the end of 2025 [1] Group 2 - The Gaoxin District has gathered over 1,400 enterprises related to the medical device and health industry, with a production value exceeding 50 billion and an annual growth rate of over 30% [2] - The district aims to continue fostering enterprise cultivation and listing as a key driver for high-quality development, enhancing the service system for the entire lifecycle of enterprises [2]
募资超6亿港元！拨康视云今日在港交所上市
Zheng Quan Shi Bao Wang·2025-07-03 06:40